Opportunity Information: Apply for PAS 16 018
Apply for PAS 16 018
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "HIV/AIDS High Priority Drug Abuse Research (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279,.
- This funding opportunity was created on Oct 27, 2015 and posted on Oct 27, 2015.
- Applicants must submit their applications by Sep 07, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The HIV/AIDS High Priority Drug Abuse Research (R01) opportunity (Funding Opportunity Number PAS 16 018) is a discretionary grant announcement from the U.S. Department of Health and Human Services, National Institutes of Health (NIH), focused on generating new, high-impact research at the intersection of drug abuse and HIV/AIDS. It is structured as an R01 research project grant, which typically supports investigator-initiated, hypothesis-driven studies that can produce publishable findings and advance the science in a defined area over a multi-year project period. The overall purpose of this FOA is to stimulate research that directly aligns with NIH HIV/AIDS priorities for the coming three to five years, as outlined in NIH Notice NOT-OD-15-137, while specifically emphasizing issues where substance use and related behaviors contribute to HIV risk, transmission, disease progression, or outcomes along the HIV prevention and care continuum.
In practical terms, the announcement is aimed at encouraging studies that address urgent and emerging needs where drug use intersects with HIV, including research that can inform prevention strategies, improve engagement and retention in HIV care, and reduce HIV-related morbidity and mortality among people who use drugs. Although the short description does not list specific topic areas, the reference to NIH-wide HIV/AIDS priorities signals that proposed projects should be clearly connected to the most pressing national HIV research directions and should make a strong case for public health relevance. Projects under this FOA would generally be expected to advance knowledge that can translate into better interventions, policies, or clinical and community practices for populations affected by substance use and HIV.
Eligibility is broad and includes many organization types that commonly participate in NIH research. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding higher education institutions in those nonprofit categories); for-profit organizations other than small businesses; small businesses; and other applicants as further clarified in the FOA text. This wide eligibility suggests NIH is open to academic, governmental, community-based, tribal, healthcare-adjacent, and private-sector entities, provided they have the research capacity and compliance infrastructure to carry out an NIH-funded R01 project.
From an administrative standpoint, the opportunity falls under the NIH awarding component listed as HHS-NIH11 and is associated with CFDA numbers 93.279 (and possibly related HIV/AIDS-relevant NIH funding streams reflected in the listing). The FOA was posted and created on October 27, 2015, and the listed application due date (closing date) is September 7, 2018. The public listing does not specify an award ceiling or the expected number of awards, which often means applicants must rely on the detailed FOA text and NIH institute funding plans to understand likely budget ranges and paylines. As with most R01 mechanisms, budgets and project scopes are typically expected to be well-justified, aligned with the scientific aims, and appropriate for the proposed research design and timeline.
Overall, this grant opportunity is best understood as a targeted call for rigorous, high-priority research that addresses how drug abuse influences HIV acquisition and transmission, access to and success in prevention tools and treatment, and broader outcomes for individuals and communities. Competitive applications would be expected to clearly map their aims to NIH HIV/AIDS priority areas, demonstrate strong scientific rationale and feasibility, and show how the proposed work could meaningfully improve HIV-related outcomes for people and populations impacted by substance use.
FAQs: HIV/AIDS High Priority Drug Abuse Research (R01) - PAS 16-018
What is the HIV/AIDS High Priority Drug Abuse Research (R01) opportunity?
This opportunity (Funding Opportunity Number PAS 16-018) is a discretionary grant announcement from the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH). It supports research focused on high-impact questions at the intersection of drug abuse and HIV/AIDS.
What type of grant mechanism is being used?
The funding mechanism is an NIH R01 research project grant. R01s typically support investigator-initiated, hypothesis-driven research designed to produce publishable findings and advance knowledge in a defined area over a multi-year project period.
What is the overall purpose of this FOA?
The purpose is to stimulate new, high-priority research aligned with NIH HIV/AIDS priorities for the coming three to five years, as described in NIH Notice NOT-OD-15-137, with a specific emphasis on how substance use and related behaviors affect HIV risk, transmission, disease progression, and outcomes across the HIV prevention and care continuum.
What kinds of research topics does this announcement encourage?
Based on the description provided, the FOA encourages studies addressing urgent and emerging needs where drug use intersects with HIV, including research that can inform prevention strategies, improve engagement and retention in HIV care, and reduce HIV-related morbidity and mortality among people who use drugs.
Does the short description list specific topic areas?
No. The short description does not list specific topic areas. However, it references NIH-wide HIV/AIDS priorities, indicating that applications should clearly connect to those national HIV research directions and emphasize public health relevance where substance use is a key factor.
How should applicants align proposed projects with NIH priorities?
Projects are expected to directly align with NIH HIV/AIDS priorities for the upcoming three to five years (as outlined in NIH Notice NOT-OD-15-137) and make a clear case for why the research addresses pressing needs related to substance use and HIV across prevention and care.
What is meant by the "HIV prevention and care continuum" in this context?
In the context provided, the HIV prevention and care continuum refers broadly to stages and outcomes related to HIV prevention tools, access to care, engagement and retention in care, treatment success, and overall HIV-related health outcomes, especially where drug use affects these steps.
What kinds of impacts are expected from funded projects?
Funded research would generally be expected to advance knowledge that could translate into improved interventions, policies, or clinical and community practices for populations affected by substance use and HIV, with the goal of improving HIV-related outcomes.
Who is eligible to apply?
Eligibility is broad and includes: state governments; county governments; city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding higher education institutions in those nonprofit categories); for-profit organizations other than small businesses; small businesses; and other applicants as further clarified in the FOA text.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized Native American tribal governments and other tribal organizations are listed as eligible applicants.
Are for-profit organizations eligible to apply?
Yes. For-profit organizations other than small businesses, as well as small businesses, are listed among eligible applicant types.
Are nonprofits eligible even if they do not have 501(c)(3) status?
Yes. The eligibility list includes nonprofit organizations with or without 501(c)(3) status, with an exclusion noted for higher education institutions in those nonprofit categories.
Are government entities eligible to apply?
Yes. The eligible applicant types include multiple government entities such as state, county, city or township, special district governments, and independent school districts.
Which federal agency and component are associated with this opportunity?
The opportunity is from HHS and administered through NIH. The awarding component listed is HHS-NIH11.
What is the CFDA number associated with this funding opportunity?
The listing indicates CFDA 93.279 (and possibly related HIV/AIDS-relevant NIH funding streams reflected in the listing).
When was this FOA posted and created?
The FOA was posted and created on October 27, 2015.
What is the application due date (closing date)?
The listed application due date (closing date) is September 7, 2018.
Is an award ceiling (maximum award amount) provided in the public listing?
No. The public listing does not specify an award ceiling.
Does the listing state the expected number of awards?
No. The public listing does not specify the expected number of awards.
How should applicants think about budgets for this R01 opportunity?
The description indicates that, as with most R01 mechanisms, budgets and project scopes are typically expected to be well-justified, aligned with the scientific aims, and appropriate for the proposed research design and timeline. The listing notes applicants may need to rely on the detailed FOA text and NIH institute funding plans to understand likely budget ranges and paylines.
What makes an application likely to be competitive under this FOA?
Based on the description provided, competitive applications would be expected to: clearly map the project aims to NIH HIV/AIDS priority areas; demonstrate strong scientific rationale and feasibility; and show how the work could meaningfully improve HIV-related outcomes for people and populations impacted by substance use.
Is this opportunity focused on prevention, treatment, or both?
Both. The description emphasizes research that can inform prevention strategies and also improve engagement and retention in HIV care, reduce morbidity and mortality, and address outcomes across the HIV prevention and care continuum where substance use is a driving factor.
What population focus is highlighted by the opportunity description?
The description highlights people who use drugs and communities affected by substance use and HIV, particularly where substance use contributes to HIV risk, transmission, disease progression, or poor outcomes in prevention and care.
Does this FOA require projects to be linked to national HIV research directions?
Yes. The description indicates that proposed projects should be clearly connected to NIH-wide HIV/AIDS priorities and the most pressing national HIV research directions, with a strong argument for public health relevance in the context of substance use and HIV.
Browse more opportunities from the same agency: HHS-NIH11
Browse more opportunities from the same category: Education, Health
Next opportunity: International Narcotics and Law Enforcement – Mexico Police Professionalization Program
Previous opportunity: BLM (Arizona), Arizona Botanical Inventory and Rare Native Plants Monitoring (ASO)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAS 16 018
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAS 16 018) also looked into and applied for these:
| Funding Opportunity |
|---|
| Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 16 012 Funding Number: RFA DA 16 012 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Genomic Data Analysis Network: Visualization Genomic Data Center (U24) Apply for RFA CA 15 019 Funding Number: RFA CA 15 019 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $660,000 |
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) Apply for RFA CA 16 005 Funding Number: RFA CA 16 005 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 16 074 Funding Number: PA 16 074 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $50,000 |
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) Apply for PA 16 075 Funding Number: PA 16 075 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R34) Apply for PA 16 073 Funding Number: PA 16 073 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $225,000 |
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01) Apply for PA 16 076 Funding Number: PA 16 076 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $500,000 |
| Behavioral Science Track Award for Rapid Transition (B/Start)(R03) Apply for PAR 16 071 Funding Number: PAR 16 071 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $75,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 16 072 Funding Number: PA 16 072 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 16 084 Funding Number: PAR 16 084 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $275,000 |
| Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp) Apply for PA 16 086 Funding Number: PA 16 086 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 16 089 Funding Number: PAR 16 089 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44) Apply for RFA CA 16 008 Funding Number: RFA CA 16 008 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01) Apply for PAR 16 105 Funding Number: PAR 16 105 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $400,000 |
| Services Planning Research in the Appalachian Region to Address Adverse Health Consequences Associated with Increased Opioid Injection Drug Use (R03) Apply for RFA DA 16 015 Funding Number: RFA DA 16 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01) Apply for PAR 16 111 Funding Number: PAR 16 111 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Increased Knowledge and Innovative Strategies to Reduce HIV Incidence-iKnow Projects (R01) Apply for PAR 16 117 Funding Number: PAR 16 117 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21) Apply for PAR 16 123 Funding Number: PAR 16 123 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3) Apply for RFA DA 17 015 Funding Number: RFA DA 17 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01) Apply for PAR 16 122 Funding Number: PAR 16 122 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAS 16 018", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.